Medically reviewed
There is a sentence that decides whether stem cell therapy is right for your dog, and almost nobody says it out loud in the sales pitch.
Stem cells do not regenerate cartilage.
That is the finding from orthopedic surgeons who work with this treatment, and it quietly demolishes the mental image most owners arrive with. People imagine a worn-out joint being resurfaced from the inside, cartilage growing back, the clock rewinding. That is not what is being sold, and any clinic that lets you keep believing it is not being straight with you.
What stem cells actually do is modulate inflammation inside the joint. That is a real and useful thing. It is just a different thing, and knowing the difference is what separates a good $3,000 decision from a bad one.
First, the disease
Osteoarthritis affects nearly one in five dogs. Cartilage breaks down, chronically and progressively, in more or less any joint, at more or less any point in a life, and the pain it produces can be severe enough to take a dog’s world apart.
Geriatric dogs are the classic patients, usually in the hip, the stifle (the knee), or the elbow. But dysplasia changes that timeline entirely: a dog with a badly formed hip or elbow can be arthritic at one or two years old, which startles people who file arthritis under old age.
The progression is familiar to anyone who has watched it: weekend hikes shrink to slow walks around the block, fetch stops being a daily event, and eventually getting up after a nap becomes something the dog visibly braces for.
Treatment runs from supplements and anti-inflammatory medication all the way to surgery. Stem cell therapy sits in an awkward middle.
What the procedure actually involves
Stem cells are the body’s own repair kit. As biological blank slates, they can become many cell types, including skin, muscle, nerve, bone, tendon, and ligament, and they exist in every organ.
In dogs, the process is more straightforward than the science sounds.
There are two categories, embryonic and somatic, the latter meaning adult. Adult cells can be drawn from bone marrow or from adipose tissue, which is to say fat, and fat wins on logistics: it is simply easier to get out of a dog. It also skips a step, because fat-derived cells require no culturing, which is why a sample can go to a lab and come back in roughly 48 hours.
Getting the fat out is a smaller operation than a spay. Surgeons typically take it from the shoulder, from the lumbar region, or from the falciform ligament, the fatty band tethering the liver to the body wall. Reckon on about 20 minutes under general anesthesia. The lab processes what comes out and returns stromal vascular fraction (SVF).
The vet then sedates the dog and injects the SVF into the affected joint or joints. It can also be given intravenously. Leftover SVF is typically banked for future treatments, which matters, because repeat injections are often part of the plan.
Safety: the honest version
On the whole, the procedure carries little risk, and the reason is that the cells are your dog’s own. The immune system has nothing to object to, so immune reactions are vanishingly rare.
The real risk is the one people skip over, which is the anesthesia required to harvest the fat. For a healthy middle-aged dog that is a small risk. For an elderly dog with heart or kidney disease, which is exactly the population most likely to have advanced arthritis, it is a conversation worth having in detail.
And there is a hard exclusion. A dog with an active infection, or with cancer, is not a candidate. Because these cells act on inflammation, they can push either of those conditions in the wrong direction. This is not a caution. It is a stop sign.
The money
Surgery, processing, and the initial injection generally run $2,000 to $3,000, which puts it in the same range as some surgical treatments.
Effectiveness is not guaranteed. Surgery may still be required if it fails.
So you are spending surgical money on a treatment that may not work and may not spare you the surgery. Whether that is a good bet depends entirely on who your dog is.
The one question that decides it
Here is the filter that orthopedic specialists actually use.
A good candidate is a dog who has already failed less invasive, less expensive treatments, and who has arthritis that would not benefit from surgery.
Read that twice, because it excludes most dogs who walk into a clinic asking about stem cells. If your dog has not yet had a proper trial of weight management, an NSAID, joint injections, and structured physical rehabilitation, you are not at the stem cell stage. If your dog has a problem that surgery would fix, surgery will probably fix it.
Stem cell therapy is for the gap between those two: the dog who is out of easy options and not a surgical candidate.
I have never regretted trying it in a dog who had genuinely run out of road. I have regretted it in dogs who were sent to me for stem cells before anyone had tried taking eight pounds off them.
There is a second, more optimistic school of thought. Some vets want to use it much earlier, especially in young dogs showing early hip dysplasia and lameness, on the argument that it beats waiting for the joint to fail and then cutting it open. The clinician who first used stem cells in dogs in the U.S., back in 2005, has been making that case for two decades.
Reported results in that population are strong. In hip dysplasia cases, practitioners report improvement in greater than 90 percent of cases: better mobility, reduced or resolved lameness, and improved quality of life, with radiographic improvement visible in some.
The strongest reported outcomes tend to involve pairing it with platelet-rich plasma (PRP), a concentrated mix of platelets and growth factors drawn from the dog’s own blood, which appears to accelerate activation of the injected cells. Once in the joint, the stem cells act as an anti-inflammatory and contribute to the reformation and structural integrity of tissues.
The dramatic cases are real. Practitioners describe dogs with severe hip osteoarthritis who could not stand up from lying down, walking and wagging within three days.
They are also not typical. A dog might turn a corner inside a week, and some do. Far more often the change accumulates over roughly 90 days. Nobody can tell you with confidence how long a round lasts, and initial protocols favor monthly injections. Rechecks land at 30, 60, and 90 days, with repeat injections if the limp comes back.
Torn knees are a different case
Stem cell therapy is also used for arthritis resulting from cranial cruciate ligament (CCL) injuries, the canine equivalent of a torn ACL. It is more common in large-breed dogs but can affect any size.
CCL injuries can sometimes be managed medically with rest and medication. Often they need surgery.
The guidance from surgeons here is clear and worth respecting: with a full CCL tear, you want the stabilization of surgery. A joint that is mechanically unstable does not become stable because you injected something into it. Stem cell therapy can be genuinely useful after the operation, during rehabilitation, particularly where the injury has come with muscle loss.
The skeptical case, which deserves a hearing
The strongest argument against stem cell therapy is not that it is dangerous. It is that we do not have good evidence it beats the cheaper options.
Academic surgeons have made this point bluntly: nothing in the literature establishes that stem cells outperform the cheaper, gentler options already sitting on the shelf. Those options include hyaluronic acid, steroids, and PRP administered on its own.
That is a serious charge, and it should hang over any $3,000 conversation. More research is needed before stem cell therapy earns a settled place in routine veterinary care.
What newer research adds
The field has moved, and it has moved in a direction that may make this entire article obsolete in a few years, for a good reason.
The old model, the one described above, requires surgery on your dog to harvest their own fat. The emerging model does not. Companies are now developing allogeneic, off-the-shelf stem cell products: donor-derived cells, manufactured in advance, delivered by simple intravenous injection with no harvest surgery and no anesthesia.
That removes the single biggest risk in the current procedure and most of its cost and complexity.
The evidence is starting to arrive. A randomized, blinded, placebo-controlled pilot study of an IV-delivered donor-derived mesenchymal stromal cell therapy enrolled 88 client-owned dogs with naturally occurring, radiographically confirmed osteoarthritis and observable lameness or pain, and reported statistically significant improvement on validated owner-reported outcome measures, with no treatment-related serious adverse events and early support for the safety of repeated dosing.
Regulatory machinery is moving too. Products in this class have been granted eligibility under the FDA’s expanded conditional approval pathway, with at least one company targeting conditional approval around 2028, and another working to bring the first FDA-approved allogeneic stem cell product to the veterinary market.
Two things follow from this, and they point in opposite directions.
If your dog is suffering now, the treatment available today is the fat-harvest version, with all its caveats, and the candidate test still applies. If your dog is comfortable and you are planning ahead, the honest advice is that this is a field about to change, and the version arriving next looks meaningfully better than the version being sold now.
Either way, the sentence at the top has not changed. Stem cells calm the joint down. They do not build it back.
References
- Gallant. “Gallant Advances Canine Osteoarthritis IV-Delivered Stem Cell Therapy with Promising Pilot Data and Expanded FDA Conditional Approval Pathway Eligibility.” gallant.com/news
- dvm360. “Pilot Study Supports IV MSC Therapy for Canine Osteoarthritis.” dvm360.com/view/pilot-study-supports-iv-msc-therapy-for-canine-osteoarthritis
- dvm360. “Veterinary Stem Cell Therapy Advances Toward FDA Approval.” dvm360.com/view/veterinary-stem-cell-therapy-advances-toward-fda-approval-with-18m-in-funding
- U.S. Food and Drug Administration, Center for Veterinary Medicine. “Conditional Approval Explained: A Resource for Veterinarians.” fda.gov/animal-veterinary
- American College of Veterinary Surgeons. “Cranial Cruciate Ligament Disease.” acvs.org/small-animal/cranial-cruciate-ligament-disease
Common questions
What does it cost?
Surgery, processing, and the initial injection generally run $2,000 to $3,000, which is comparable to some surgical treatments. Effectiveness is not guaranteed, and surgery may still be needed if it fails.
Is it safe?
Generally yes. The main risk is the general anesthesia required to harvest fat. Because the cells come from your dog's own body, immune reactions are extremely rare.
Who should not get it?
Dogs with infections or cancer. Stem cells target inflammation and can make those conditions worse. This is a hard exclusion, not a caution.
How fast does it work?
Some dogs improve within the first week. More commonly, improvement appears over about 90 days. Dogs are typically rechecked at 30, 60, and 90 days, and injections may be repeated if lameness returns.
